Similar to other studies [15, 28], such expression of CRBN protein was not associated with treatment response in the regimen without IMiDs (e.g., MVP), suggesting that CRBN is a unique biomarker for predicting the response of IMiDs in MM patients. This evidence concerns the gene CRBN and Miyoshi myopathy.